RPCEC00000332已完成1 期
Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01
Finlay Vaccine Institute (IFV)0 个研究点目标入组 676 人开始时间: 2020年8月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 676
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Parallel. Purpose: Prevention
入排标准
- 年龄范围
- 19 years 至 80 years（—）
- 性别
- All
入选标准
- •1. Subjects who give written informed consent to participate in the study.
- •2. Subjects aged between 19-59 and 60-80 years.
- •3. Body mass index between 18 and 29.9 kg / m2.
- •4. Women of childbearing potential using safe contraceptive methods during the study.
- •5. General, regional and apparatus physical examination: normal or without clinically significant alterations.
- •6. Clinical Laboratory testing within the range of reference values, or outside ??but not clinically significant (Only for Phase I)
排除标准
- •1. Subjects with acute febrile or infectious disease in the 7 days prior to the administration of the vaccine or at the time of its application.
- •2. Subjects treated with antimicrobials or NSAIDs in the 7 days prior to the administration of the vaccine.
- •3. Subjects with non-trasmisible chronic diseases not controlled according to clinical or laboratory criteria (bronchial asthma, chronic obstructive pulmonary disease, ischemic heart disease, arterial hypertension, diabetes mellitus, thyroid, neurological, hemolymphopoietic system diseases, psychiatric disease at a psychotic level) .
- •4. Subjects with congenital or acquired immune system disease.
- •5. Subjects with a history of unresolved neoplastic disease.
- •6. Subjects with a personal history of liver or kidney failure.
- •7. Subjects with a history of substance abuse in the past 30 days or substance addictive illness, except withdrawal.
- •8. Subjects with diminished mental faculties.
- •9. Subjects with a history of severe allergic disease (anaphylactic shock, angioneurotic edema, glottis edema, severe urticaria).
- •10. Subjects with a history of hypersensitivity to thiomersal or other component of the formulation.
- •11. Subjects with a history of SARS and COVID-19 who meet any of the following criteria:
- •a) Previous or current history of SARS-CoV 2 infection.
- •b) Be declared in the category of contact or suspect at the time of inclusion
- •c) Subject with positive rapid test for SARS-CoV 2.
- •d) Patient with a positive PCR at the time of inclusion.
- •12. Participation in another clinical trial in the last 3 months.
- •13. Application of another vaccine in the last 30 days.
- •14. Treatment with immunomodulators in the last 30 days (eg steroids (except topical and inhaled), cytostatics, interferon, immunoferon, transfer factor, monoclonal antibody, Biomodulin T, any gammaglobulin, Levamisole, Heberferon, thymosin) or predictably those people that due to their underlying disease could require immunomodulatory treatment during the study.
- •15. Transfusion of blood or blood products in the last 3 months for phase I and last 30 days for phase II.
- •16. Patients with difficulties in attending planned follow-up visits.
- •17. Splenectomy or splenic dysfunction.
- •18. Pregnancy, puerperium or lactation.
研究者
相似试验
已完成
1 期
SOBERANA 01APrevention of COVID-19 diseaseCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusDisease PreventionRPCEC00000338Finlay Vaccine Institute (IFV)60
进行中（未招募）
1 期
A study to evaluate the safety and the efficacy of a sterile bio-compatible patch (sFilm-FS) in controlling bleeding during hepatic surgery.EUCTR2018-000434-34-SISealantium Medical Ltd.30
进行中（未招募）
1 期
A study to evaluate the safety and the efficacy of a sterile bio-compatible patch (sFilm-FS) in controlling bleeding during hepatic surgery.Open hepatic surgery, with presence of an target bleeding site (TBS).MedDRA version: 21.1Level: LLTClassification code 10067440Term: HemostasisSystem Organ Class: 100000004865EUCTR2018-000434-34-ATSealantium Medical Ltd.30
尚未招募
1 期
FACA Syrup clinical trialPACTR202407870029422Institut de Recherche en Sciences de la Sante10
进行中（未招募）
不适用
Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccines M72/AS01B and M72/AS02A when administered intramuscularly according to a vaccination schedule of 0, 1 month, to healthy PPD-negative adults aged 18 to 50 years. - TUBERCULOSIS-005,TUBERCULOSIS-006 EXT:005 Y1,TUBERCULOSIS-007 EXT:005 Y2,TUBERCULOSIS-008 EXT:005 Y3Vaccination against tuberculosisEUCTR2005-004497-24-BEGlaxoSmithKline Biologicals